Table 5. Univariate analysis of outcomes... | American Society of Hematology

Table 5.

Univariate analysis of outcomes for recipients of UDLI for relapsed disease (n = 58)

Predictors	Acute GVHD (Yes/No)^5-150P Value	Acute GVHD Grade (0-I vs II-IV)^5-150P Value	Survival^5-151P Value (Hazard Ratio)	Disease- free Survival^5-151P Value (Hazard Ratio)
Age	ns	ns	ns	ns
Sex	ns	ns	ns	ns
Sex mismatch	ns	ns	ns	ns
HLA match grade (matched vs mismatched)	ns	ns	ns	ns
Time, BMT to relapse	ns	ns	.018 (0.99)	.028 (0.98)
BMT to relapse more than 1 year	ns	ns	.0006	.001
Time, BMT to UDLI	ns	ns	.003 (0.99)	.067 (0.98)
BMT to UDLI more than 1 year	ns	ns	.001	.0001
Acute GVHD after BMT	ns	ns	.06	.022
Chronic GVHD after BMT	ns	ns	ns	ns
T-cell–depleted marrow graft	ns	ns	.03	.014
UDLI for CML vs other	ns	ns	.034	.033

Predictors	Acute GVHD (Yes/No)^5-150P Value	Acute GVHD Grade (0-I vs II-IV)^5-150P Value	Survival^5-151P Value (Hazard Ratio)	Disease- free Survival^5-151P Value (Hazard Ratio)
Age	ns	ns	ns	ns
Sex	ns	ns	ns	ns
Sex mismatch	ns	ns	ns	ns
HLA match grade (matched vs mismatched)	ns	ns	ns	ns
Time, BMT to relapse	ns	ns	.018 (0.99)	.028 (0.98)
BMT to relapse more than 1 year	ns	ns	.0006	.001
Time, BMT to UDLI	ns	ns	.003 (0.99)	.067 (0.98)
BMT to UDLI more than 1 year	ns	ns	.001	.0001
Acute GVHD after BMT	ns	ns	.06	.022
Chronic GVHD after BMT	ns	ns	ns	ns
T-cell–depleted marrow graft	ns	ns	.03	.014
UDLI for CML vs other	ns	ns	.034	.033

ns indicates not significant.

Logistic regression analysis.

Log-rank test or proportional hazards regression analysis.